Published in Curr Opin Oncol on November 01, 2003
Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones (2005) 5.22
Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell (2007) 3.50
RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell (2007) 3.09
Multiple conformations of E. coli Hsp90 in solution: insights into the conformational dynamics of Hsp90. Structure (2008) 2.98
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A (2005) 2.93
Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol (2007) 2.25
Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest (2005) 2.06
Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update. Arch Toxicol (2012) 2.04
Physiological regulation of Akt activity and stability. Am J Transl Res (2010) 1.95
Transforming growth factor alpha (TGFalpha)-stimulated secretion of HSP90alpha: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFbeta-rich environment during wound healing. Mol Cell Biol (2008) 1.88
Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem (2008) 1.84
Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest (2009) 1.72
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol (2008) 1.65
Intra- and intermonomer interactions are required to synergistically facilitate ATP hydrolysis in Hsp90. J Biol Chem (2008) 1.64
Conformational dynamics of the molecular chaperone Hsp90. Q Rev Biophys (2011) 1.61
The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J Org Chem (2008) 1.49
Hsp90: A New Player in DNA Repair? Biomolecules (2015) 1.45
Herpes simplex virus type 1 DNA polymerase requires the mammalian chaperone hsp90 for proper localization to the nucleus. J Virol (2005) 1.40
Endocytosis and cancer. Cold Spring Harb Perspect Biol (2013) 1.40
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene (2011) 1.38
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood (2005) 1.38
Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer (2008) 1.32
To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future Med Chem (2009) 1.29
Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis. J Cell Mol Med (2008) 1.27
Extracellular heat shock protein (Hsp)70 and Hsp90α assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One (2011) 1.25
pH-dependent conformational changes in bacterial Hsp90 reveal a Grp94-like conformation at pH 6 that is highly active in suppression of citrate synthase aggregation. J Mol Biol (2009) 1.19
JNK1 mediates degradation HIF-1alpha by a VHL-independent mechanism that involves the chaperones Hsp90/Hsp70. Cancer Res (2010) 1.18
Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer (2010) 1.12
Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol (2005) 1.11
Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One (2009) 1.09
Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res (2012) 1.09
Hsp90 modulates CAG repeat instability in human cells. Cell Stress Chaperones (2010) 1.09
(-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry (2009) 1.06
Heat shock proteins in breast cancer progression--a suitable case for treatment? Int J Hyperthermia (2010) 1.06
Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives. Bioorg Med Chem (2010) 1.04
Heat shock protein 90-mediated inactivation of nuclear factor-κB switches autophagy to apoptosis through becn1 transcriptional inhibition in selenite-induced NB4 cells. Mol Biol Cell (2011) 1.04
Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects. Cancer Res (2008) 1.03
Mechanistic studies of Sansalvamide A-amide: an allosteric modulator of Hsp90. ACS Med Chem Lett (2010) 1.02
Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells. Clin Cancer Res (2008) 1.02
Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin. Br J Cancer (2009) 1.02
17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer (2010) 1.00
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol (2009) 1.00
Mechanisms of ErbB receptor negative regulation and relevance in cancer. Exp Cell Res (2008) 0.99
Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics (2010) 0.99
Understanding ligand-based modulation of the Hsp90 molecular chaperone dynamics at atomic resolution. Proc Natl Acad Sci U S A (2008) 0.98
Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent. J Transl Med (2011) 0.97
Regulation of proto-oncogenic dbl by chaperone-controlled, ubiquitin-mediated degradation. Mol Cell Biol (2006) 0.97
Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma. PLoS One (2011) 0.96
Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers. Breast Cancer Res (2010) 0.96
HILI inhibits TGF-β signaling by interacting with Hsp90 and promoting TβR degradation. PLoS One (2012) 0.95
Correlation between mitochondrial TRAP-1 expression and lymph node metastasis in colorectal cancer. World J Gastroenterol (2012) 0.94
Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors. Anticancer Res (2006) 0.94
The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate (2008) 0.93
Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins. ACS Chem Biol (2011) 0.93
Molecular cochaperones: tumor growth and cancer treatment. Scientifica (Cairo) (2013) 0.92
Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer. Oncologist (2012) 0.91
A heat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair. PLoS One (2012) 0.90
Small molecule activators of the heat shock response: chemical properties, molecular targets, and therapeutic promise. Chem Res Toxicol (2012) 0.86
Isoflavone-deprived soy peptide suppresses mammary tumorigenesis by inducing apoptosis. Exp Mol Med (2009) 0.85
Heat shock protein 90 inhibitors prevent LPS-induced endothelial barrier dysfunction by disrupting RhoA signaling. Am J Respir Cell Mol Biol (2014) 0.85
A new feature of the stress response: increase in endocytosis mediated by Hsp70. Cell Stress Chaperones (2009) 0.85
Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling. Bioorg Med Chem (2008) 0.85
HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells. Cell Signal (2014) 0.84
Pnck induces ligand-independent EGFR degradation by probable perturbation of the Hsp90 chaperone complex. Am J Physiol Cell Physiol (2011) 0.83
A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response. Bioorg Med Chem Lett (2013) 0.83
Kadota Fund International Forum 2004. Application of thermal stress for the improvement of health, 15-18 June 2004, Awaji Yumebutai International Conference Center, Awaji Island, Hyogo, Japan. Final report. Int J Hyperthermia (2008) 0.82
Hepatitis B virus polymerase suppresses NF-κB signaling by inhibiting the activity of IKKs via interaction with Hsp90β. PLoS One (2014) 0.82
Targeting the 90 kDa heat shock protein improves photodynamic therapy. Cancer Lett (2009) 0.82
Two HSPs gene from juvenile Amur sturgeon (Acipenser schrenckii): cloning, characterization and expression pattern to crowding and hypoxia stress. Fish Physiol Biochem (2014) 0.82
NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma. Biomed Res Int (2015) 0.81
Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention. J Alzheimers Dis Parkinsonism (2013) 0.81
Proteomic identification of tumor biomarkers associated with primary gallbladder cancer. World J Gastroenterol (2014) 0.79
Geldanamycin induces production of heat shock protein 70 and partially attenuates ototoxicity caused by gentamicin in the organ of Corti explants. J Biomed Sci (2009) 0.79
Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.79
Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma (2009) 0.79
Heat shock protein 90: role in enterovirus 71 entry and assembly and potential target for therapy. PLoS One (2013) 0.78
Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathway. Diagn Pathol (2013) 0.78
Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. Ther Adv Urol (2015) 0.78
Proteomics analysis reveals protein expression differences for hypopharyngeal gland activity in the honeybee, Apis mellifera carnica Pollmann. BMC Genomics (2014) 0.78
Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects. Proc Natl Acad Sci U S A (2012) 0.78
Effects of the novel heat shock protein 90 inhibitor AUY922 in renal cell carcinoma ACHN and 786-O cells. Oncol Lett (2015) 0.76
Heat shock proteins at the crossroads between cancer and Alzheimer's disease. Biomed Res Int (2014) 0.76
Chemically accessible hsp90 inhibitor that does not induce a heat shock response. ACS Med Chem Lett (2014) 0.76
Exosomes in cancer theranostic: Diamonds in the rough. Cell Adh Migr (2017) 0.75
Canonical hedgehog signaling regulates hepatic stellate cell-mediated angiogenesis in liver fibrosis. Br J Pharmacol (2017) 0.75
Adenomatous polyposis coli mutants dominantly activate Hsf1-dependent cell stress pathways through inhibition of microtubule dynamics. Oncotarget (2015) 0.75
Identification of host cellular proteins that interact with the M protein of a highly pathogenic porcine reproductive and respiratory syndrome virus vaccine strain. Virol J (2017) 0.75
Effectively delivering a unique hsp90 inhibitor using star polymers. ACS Med Chem Lett (2013) 0.75
HSP90 as a novel molecular target in non-small-cell lung cancer. Lung Cancer (Auckl) (2016) 0.75
Molecular chaperone therapy- the future in cancer. Infect Agent Cancer (2012) 0.75
Stressing Out Hsp90 in Neurotoxic Proteinopathies. Curr Top Med Chem (2016) 0.75
Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells. Oncotarget (2016) 0.75
Molecular docking and pharmacophore studies of heterocyclic compounds as Heat shock protein 90 (Hsp90) Inhibitors. Bioinformation (2016) 0.75
SGT1-HSP90 Complex Is Required for CENP-A Deposition at Centromeres. Cell Cycle (2017) 0.75
Effects of 17-DMAG on diffuse large B-cell lymphoma cell apoptosis. Exp Ther Med (2017) 0.75
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol (2010) 4.22
Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol (2005) 3.36
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res (2007) 2.50
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A (2013) 2.14
Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol (2013) 1.99
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res (2005) 1.97
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res (2007) 1.92
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol (2008) 1.87
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.85
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res (2007) 1.80
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst (2010) 1.73
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol (2008) 1.69
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res (2007) 1.61
Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res (2011) 1.57
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2008) 1.56
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol (2010) 1.38
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol (2010) 1.15
Controversies in cancer stem cells: targeting embryonic signaling pathways. Clin Cancer Res (2010) 1.12
Developing standards for breakthrough therapy designation in oncology. Clin Cancer Res (2013) 1.09
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol (2010) 1.07
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.04
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer (2010) 1.04
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest New Drugs (2013) 0.99
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest New Drugs (2010) 0.98
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol (2011) 0.96
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Invest New Drugs (2013) 0.95
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica (2011) 0.92
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol (2011) 0.89
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol (2011) 0.89
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res (2013) 0.87
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions. Cancer Chemother Pharmacol (2005) 0.84
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Invest New Drugs (2013) 0.84
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors. Clin Cancer Res (2007) 0.84
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. Invest New Drugs (2012) 0.84
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J (2012) 0.83
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. Leuk Lymphoma (2011) 0.82
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatr Blood Cancer (2012) 0.81
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemother Pharmacol (2010) 0.81
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies. Clin Cancer Res (2013) 0.81
Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol (2010) 0.81
Molecular conversations and the development of the hair follicle and basal cell carcinoma. Cancer Prev Res (Phila) (2010) 0.80
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs (2014) 0.80
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. Cancer Res (2004) 0.80
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Cancer Chemother Pharmacol (2005) 0.78
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol (2008) 0.78
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. Haematologica (2013) 0.77
A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer. Int J Radiat Oncol Biol Phys (2012) 0.77
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemother Pharmacol (2008) 0.75
Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience. J Biopharm Stat (2009) 0.75
Challenges and Opportunities for Immunotherapies in Gynecologic Cancers. Oncology (Williston Park) (2016) 0.75
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011. Melanoma Res (2013) 0.75
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. Leuk Lymphoma (2014) 0.75